Cat. No.: HY-N3011

Iridin

Avis client

Based on 1 Customer Validation

Iridin is an orally active natural isoflavone. Iridin inhibits the PI3K/AKT and PKM2 signaling pathways, and downregulates the JAK/STAT and NF-κB pathways. Iridin induces Fas-mediated extrinsic apoptosis, G2/M cell cycle arrest, and inhibits cell proliferation. Iridin reduces inflammation, inhibits ROS production, suppresses glycolysis, and also exhibits antioxidant and antidiabetic activities. Iridin can be used in research related to gastric cancer and acute lung injury.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.72%
CAS No.: 491-74-7
Formule: C₂₄H₂₆O₁₃
Masse moléculaire:522.46

Stockage:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Iridin Chemical Structure

CAS No.: 491-74-7

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
- In Vivo
Chemical Information
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform PI3K :

Voir tous les produits spécifiques à Isoform Akt :

Voir tous les produits spécifiques à Isoform JAK :

Voir tous les produits spécifiques à Isoform STAT :

Voir tous les produits spécifiques à Isoform NF-κB :

In Vitro

Iridin (12.5-200 μM) induces apoptosis via the extrinsic pathway and regulates the PI3K/AKT signaling pathway in AGS gastric cancer cells, HaCaT cells, and TRAIL-resistant gastric cancer cells^[1].
Iridin (12.5-50 μM; 18 h) inhibits the production of proinflammatory mediators in LPS (HY-D1056)-stimulated RAW 264.7 cells in a dose-dependent manner^[1].
Iridin (10 nM-100 μM) exerts no anticancer effects on MCF-7 and T-47D breast cancer cells^[1].
Iridin (12.5-200 μM; 48 h) inhibits the proliferation and induces the death of human gastric cancer AGS cells, with an IC₅₀ of 161.3 μM; whereas it exerts no significant effect on the cell viability of human keratinocyte HaCaT cells after 48 h of treatment^[2].
Iridin (50-200 μM; 48 h) induces G2/M cell cycle arrest in human gastric cancer AGS cells after 48 h of treatment by downregulating the expression of cell cycle regulatory proteins Cdc25C, CDK1, and Cyclin B1^[2].
Iridin (50-200 μM; 48 h) induces apoptotic cell death in human gastric cancer AGS cells via the extrinsic apoptotic pathway^[2].
Iridin (50-200 μM; 48 h) inhibits the PI3K/AKT signaling pathway in human gastric cancer AGS cells by downregulating the phosphorylated (active) forms of PI3K and AKT, without affecting the expression of total PI3K or AKT^[2].
Iridin (6.25-200 μM; 24 h) shows no cytotoxicity against RAW264.7 cells even at concentrations up to 100 μM. Based on its anti-inflammatory efficacy, concentrations of 12.5, 25 and 50 μM are selected for subsequent studies^[3].
Iridin (12.5-50 μM; 18 h) reverses LPS-induced Warburg effect in RAW264.7 cells in a dose-dependent manner by enhancing oxidative phosphorylation and reducing glycolytic activity^[3].
Iridin (12.5-50 μM; 18 h) dose-dependently inhibits LPS-induced production of NO, TNF-α, IL-1β and MCP-1 in RAW264.7 cells^[3].
Iridin (12.5-50 μM; 18 h) dose-dependently abrogates LPS-induced accumulation of ROS and NO in RAW264.7 cells^[3].
Iridin (12.5-50 μM; 18 h) dose-dependently inhibits LPS-induced excessive phagocytic activity in RAW264.7 cells^[3].
Iridin (12.5-50 μM; 18 h) dose-dependently downregulates the expression of PKM2 and its downstream JAK/STAT and NF-κB pathway proteins in LPS-stimulated RAW264.7 cells, and this effect is reversed by PKM2 activation or ROS scavenging^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

human gastric cancer AGS cells, human keratinocyte HaCaT cells
Concentration:

12.5, 25, 50, 100 and 200 μM
Incubation Time:

48 h
Result:

Caused a concentration-dependent reduction in AGS cell viability, with an IC₅₀ of 161.3 μM.
Did not significantly affect HaCaT cell viability at any tested concentration.
Induced morphological changes in AGS cells including floating dead cells, cell shrinkage, and reduced cell numbers.

Cell Cycle Analysis^[2]

Cell Line:

human gastric cancer AGS cells
Concentration:

50, 100 and 200 μM
Incubation Time:

48 h
Result:

Caused a concentration-dependent increase in the percentage of AGS cells arrested in the G2/M phase, accompanied by reduced percentages of cells in the G0/G1 phase.
Downregulated Cdc25C, CDK1, and Cyclin B1 protein expression in a concentration-dependent manner compared to untreated controls.

Apoptosis Analysis^[2]

Cell Line:

human gastric cancer AGS cells
Concentration:

50, 100 and 200 μM
Incubation Time:

48 h
Result:

Caused a concentration-dependent increase in the apoptotic cell fraction (early apoptosis) in AGS cells, with apoptotic cell percentages rising significantly at 50, 100, and 200 μM.
Upregulated cleaved Caspase-3 and cleaved PARP protein expression in a concentration-dependent manner, along with downregulation of full-length Caspase-3 and PARP.

Western Blot Analysis^[2]

Cell Line:

human gastric cancer AGS cells
Concentration:

50, 100 and 200 μM
Incubation Time:

48 h
Result:

Upregulated Fas and FasL protein expression in a concentration-dependent manner.
Downregulated full-length Caspase-8 and upregulated cleaved Caspase-8 in a concentration-dependent manner.
Caused no significant changes in the expression levels of Bcl-xL, Bax, Caspase-9, or cleaved Caspase-9 compared to untreated controls.\nDownregulated p-PI3K and p-AKT protein expression in a concentration-dependent manner.
Caused no changes in the expression levels of total PI3K and total AKT compared to untreated controls.

Cell Cytotoxicity Assay^[3]

Cell Line:

murine macrophage RAW264.7 cells
Concentration:

6.25, 12.5, 25, 50, 100, 150, 200 μM
Incubation Time:

24 h
Result:

Did not affect RAW264.7 cell proliferation at concentrations ≤100 μM, with no significant difference in cell viability between control, Iridin-only, and LPS+Iridin groups (P>0.05).
Selected concentrations of 12.5, 25, and 50 μM for subsequent experiments based on an IC₅₀ of 24.8 μM for LPS-induced NO release.

Western Blot Analysis^[3]

Cell Line:

LPS-stimulated murine macrophage RAW264.7 cells
Concentration:

12.5, 25, 50 μM
Incubation Time:

2 h pre-incubation, followed by 16 h LPS stimulation
Result:

Dose-dependently reduced the expression of PKM2, p-JAK1, p-STAT1, p-STAT3, p-p65, iNOS, and COX2 proteins.
Inhibitory effects were fully reversed by PKM2 agonist DASA-58 or antioxidant NAC, and partially reversed by NF-κB activator CUT129 or JAK1 activator RO8191.

In Vivo

Iridin (20-80 mg/kg; p.o.; once daily; 5 days) dose-dependently ameliorates LPS-induced acute lung injury in male ICR mice by reducing inflammatory cell infiltration, modulating macrophage polarization to an anti-inflammatory M2 phenotype, and inhibiting the PKM2-mediated JAK/STAT and NF-κB signaling pathways^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

ICR (male, 24 g body weight, LPS-induced acute lung injury model)^[3]
Dosage:

20 mg/kg; 40 mg/kg; 80 mg/kg
Administration:

p.o.; once daily; 5 days
Result:

Dose-dependently reduced lung pathologic scores, lung index, total cell count, and neutrophil count in bronchoalveolar lavage fluid compared to the LPS-challenged model group.
Dose-dependently decreased serum levels of iNOS and TNF-α, and increased serum levels of IL-10 compared to the LPS-challenged model group.
Dose-dependently reduced mRNA expressions of M1 macrophage markers iNOS and TNF-α, and increased mRNA expressions of M2 macrophage markers IL-10 and Arg-1 in lung tissue macrophages compared to the LPS-challenged model group.
Dose-dependently downregulated protein expressions of PKM2, p-JAK1, p-STAT1, p-STAT3, p-p65, iNOS, and COX2 in lung tissues compared to the LPS-challenged model group.

Chemical Information

CAS No. 491-74-7
Appearance Solid
Masse moléculaire 522.46
Formule C₂₄H₂₆O₁₃
Color White to off-white
SMILES

O=C1C2=C(O)C(OC)=C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)CO)C=C2OC=C1C4=CC(OC)=C(OC)C(O)=C4
Structure Classification
- Flavonoids
- Isoflavones
- Phenols
- Polyphenols
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (191.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9140 mL

9.5701 mL

19.1402 mL

5 mM

0.3828 mL

1.9140 mL

3.8280 mL

10 mM

0.1914 mL

0.9570 mL

1.9140 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (287 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Won Y, et al. The Effects of Iridin and Irigenin on Cancer: Comparison with Well-Known Isoflavones in Breast, Prostate, and Gastric Cancers. Int J Mol Sci. 2025;26(6):2390. Published 2025 Mar 7. [Content Brief]

[2]. Bhosale PB, et al. Iridin Induces G2/M Phase Cell Cycle Arrest and Extrinsic Apoptotic Cell Death through PI3K/AKT Signaling Pathway in AGS Gastric Cancer Cells. Molecules. 2021;26(9):2802. Published 2021 May 10. [Content Brief]

[3]. Ying ZH, et al. Iridin Prevented Against Lipopolysaccharide-Induced Inflammatory Responses of Macrophages via Inactivation of PKM2-Mediated Glycolytic Pathways. J Inflamm Res. 2021;14:341-354. Published 2021 Feb 5. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9140 mL	9.5701 mL	19.1402 mL	47.8506 mL
	5 mM	0.3828 mL	1.9140 mL	3.8280 mL	9.5701 mL
	10 mM	0.1914 mL	0.9570 mL	1.9140 mL	4.7851 mL
	15 mM	0.1276 mL	0.6380 mL	1.2760 mL	3.1900 mL
	20 mM	0.0957 mL	0.4785 mL	0.9570 mL	2.3925 mL
	25 mM	0.0766 mL	0.3828 mL	0.7656 mL	1.9140 mL
	30 mM	0.0638 mL	0.3190 mL	0.6380 mL	1.5950 mL
	40 mM	0.0479 mL	0.2393 mL	0.4785 mL	1.1963 mL
	50 mM	0.0383 mL	0.1914 mL	0.3828 mL	0.9570 mL
	60 mM	0.0319 mL	0.1595 mL	0.3190 mL	0.7975 mL
	80 mM	0.0239 mL	0.1196 mL	0.2393 mL	0.5981 mL
	100 mM	0.0191 mL	0.0957 mL	0.1914 mL	0.4785 mL

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Iridin

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-diabetic Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Phenols Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Autoimmune Disease Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library